All News

This year, some of the most-read peer-reviewed research published in The American Journal of Managed Care® (AJMC®) explored cost-saving models of care, the benefits and hazards of health information technology, effects of incorporating Choosing Wisely principles into clinical decision support tools, and more.

A new poll has found that most Americans support gene editing that is used to protect babies against diseases; Maine’s incoming governor, a Democrat, may be able to ignore the Medicaid work requirements the federal government just approved for the outgoing Republican governor; the new trade agreement between the United States, Canada, and Mexico includes language that could delay cheaper generics from reaching patients.

The Hospital Readmission Reduction Program was announced as part of the Affordable Care Act and penalized hospitals for higher-than-expected 30-day readmissions. However, new research finds that the policy may have done more harm than good with postdischarge mortality increasing for Medicare beneficiaries hospitalized for heart failure and pneumonia.

Of US women between the ages of 15 and 49, 64.9% use some form of contraception, and the use of long-acting reversible contraceptives is increasing; people with prolonged opioid use have an increased risk for cardiovascular problems, but they are also more likely to develop major surgery complications; there are an estimated 11 million undocumented immigrants in the United States, and they struggle to receive basic medical care.

In 2018, articles in The American Journal of Accountable Care® (AJAC) analyzed experiences within accountable care organizations (ACOs), the cost-effectiveness of initiatives to prevent readmissions, and much more. Here are the top 5 most-read articles published in AJAC in 2018.

Michigan’s plan to require Medicaid beneficiaries to show workforce engagement was approved by the Trump administration, while attorneys continue to challenge Arkansas’ own Medicaid work requirements; a new report from the Government Accountability Office has highlighted serious deficiencies with how the FDA administers the Orphan Drug Act; the FDA has granted tentative approval to a weekly and monthly treatment for moderate-to-severe opioid use disorder (OUD), but cannot grant final approval until another treatment’s exclusivity period ends.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text